DURATION OF ACTION AND PHARMACOKINETICS OF THE ORAL ANTIDIABETIC DRUGGLIQUIDONE IN PATIENTS WITH NON-INSULIN-DEPENDENT (TYPE-2) DIABETES-MELLITUS

The duration of action and the pharmacokinetics of gliquidone xo-2(1H) -isochinolyl)ethyl]phenyl]-sulfonyl]-urea, AR-DF 26 SE, CAS 33342-05-1 , Glurenorm(R), Beglynor(R)) were investigated in 32 patients with non -insulin-dependent (type 2) diabetes mellitus over 16 h. In a single-b linded cross-over design vs. placebo, one 30 mg tablet gliquidone was administered 15 min before breakfast. Concomitant to the measurement o f glucose and insulin, the gliquidone plasma levels of 20 subjects wer e determined by a new specific liquid chromatographic (HPLC) assay met hod with fluorescence detection, and the pharmacokinetic parameters ca lculated.